Cefotaxime, desacetyl-cefotaxime, and bactericidal activity in spontaneous bacterial peritonitis

Journal of Infectious Diseases

Volumn 180, Issue 5, 1999, Pages 1597-1602

  Dalmau, David ^a,b   Layrargues, Gilles Pomier ^a   Fenyves, Daphna ^a   Willems, Bernard ^a   Turgeon, Fernand ^a   Turgeon, Pierre ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HOSPITAL MÚTUA DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; DEACETYLCEFOTAXIME;

ADULT; AGED; ARTICLE; ASCITES FLUID; BACTERIAL PERITONITIS; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; BACTERIA; BACTERIAL INFECTIONS; CEFOTAXIME; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONITIS; PROSPECTIVE STUDIES;

EID: 0032751407     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315053     Document Type: Article

References (36)

1. 1. Conn HO, Fessel JM. Spontaneous bacterial peritonitis in cirrhosis: variations of a theme. Medicine 1971;50:161-92.
2. 2. Pinzello G, Simonettic RG, Craxi A, et al. Spontaneous bacterial peritonitis: a prospective investigation in predominantly non-alcoholic cirrhotic patients. Hepatology 1983;3:545-9.
3. 3. Felisart J, Rimola A, Arroyo V, et al. Cefotaxime is more effective than is ampicillin-tobramycin in cirrhotics with severe infections. Hepatology 1985;5:457-62.
4. 4. Ariza J, Xiol X, Esteve M, et al. Aztreonam versus cefotaxime in the treatment of gram negative spontaneous peritonitis in cirrhotic patients. Hepatology 1991;14:91-8.
5. 5. Toledo C, Salmerón JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. Hepatology 1993;17:251-7.
6. 6. Runyon BA, McHutchison JG, Antillon MR, Akriviadis EA, Montano AA. Short course versus long course antibiotic treatment of spontaneous bacterial peritonitis. Gastroenterology 1991;100:1737-42.
7. 7. Rimola A, Sulmerón JM, Clemente G, et al. Two different dosages of cefotaxime in the treatment of spontaneous bacterial peritonitis: results of a prospective, randomized, multicenler study. Hepatology 1995;21:674-9.
8. 8. Trenholme GM, Schmitt BA, Nelson JA, Gvazdinskas LC, Harrison BB, Parkhurst GW. Comparative study of three different dosing regimens of cefotaxime for treatment of gram-negative bacteremia. Diagn Microbiol Infect Dis 1989;12:107-11.
9. 9. Doluisio JT. Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. Rev Infect Dis 1982;4:S333-45.
10. 10. Novick WJ Jr. Levels of cefotaxime in body fluids and tissues: a review. Rev Infect Dis 1982;4:S346-53.
11. 11. Moreau L, Durand H, Biclet P, Cefotaxime concentration in ascites. J Antimicrob Chemother 1980;6(Suppl A):121-2.
12. 12. Graninger W, Vihlein M, Ferenci P, Moser C, Gergopoulos A. Cefotaxime and desacetyl-cefotaxime blood levels in hepatic disfunction. J Antimicrob Chemother 1984;14(Suppl B):143-6.
13. 13. Hoffken G, Lode H, Koeppe P, Ruhnke M, Borner K. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in cirrhosis of the liver. Chemotherapy 1984;30:7-17.
14. 14. Ko RJ, Sattler FR, Nichols S, et al. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in patients with liver disease. Antimicrob Agents Chemother 1991;35:1376-80.
15. 15. Westphal JF, Jehl F, Vetter D. Pharmacological, toxicologic and microbiologic considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. Clin Infect Dis 1994;18:324-35.
16. 16. Papadakis MA, Arieff AT. Unpredictability of clinical evaluation of renal function in cirrhosis: prospective study. Am J Med 1987;82:945-52.
17. 17. Jones RN. Cefotaxime and desacetyl-cefotaxime antimicrobial interactions. Diagn Microbiol Infect Dis 1995;22:19-33.
18. 18. Wise R, Wills PJ, Andrews JM, Bedford KA. Activity of the cefotaxime (HR756) desacetyl metabolite compared with dose of cefotaxime and other cephalosporins. Antimicrob Agents Chemother 1980;17:84-6.
19. 19. Neu HC. Antibacterial activity of desacetyl-cefotaxime alone and in combination with cefotaxime. Rev Infect Dis 1982;(Suppl):S374-78.
20. 20. Stevens DL, Bergstrom R, Gibbons A. Synergistic interaction of cefotaxime and its metabolite desacetyl-cefotaxime demonstrated by drug-impregnated disks. Diagn Microbiol Infect Dis 1989;12:73-80.
21. 21. Weinstein MP, Stratton CW, Ackley A, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med 1985;78:262-9.
22. 22. Weinstein MP, Stratton CN, Hawley HB, et al. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med 1987;83: 218-22.
23. 23. Chabbert YA. Le laboratoire d'antibiothérapie dans les meningites purulentes. Sem Hop Paris 1967;43:239.
24. 24. Pugh RNH, Murray-Lyon MM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
25. 25. National Committee for Clinical Laboratory Standards 1993. Methtods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. (3rd, ed.). Approved standards M7-A3. Vilanova, Pa.: NCCLS, 1993.
26. 26. National Committee for Clinical Standards 1987. Methods for determining bactericidal activity of antimicrobial agents: proposed guideline. NCCLS document M26-P. Vilanova, Pa.: NCCLS, 1987.
27. 27. National Committee for Clinical Laboratory Standards 1992. Methodology on the serum bactericidal test: tentative guideline. NCCLS document M21-T. Vilanova, Pa.: NCCLS, 1992.
28. 28. Vallée F, LeBel M. Comparative study of pharmacokinetics and serum bactericidal activity of ceftizoxime and cefotaxime. Antimicrob Agents Chemother 1991;35:2057-64.
29. 29. Runyon BA, Morrissey RL, Hoefs JC, Wyle FA. Opsonic activity of human ascitic fluid: a potentially important protective mechanism against SBP. Hepatology 1985;5:634-7.
30. 30. Akalin HE, Lalely Y, Telatar H. Bactericidal opsonic activity of ascitic fluid from cirrhotic and non cirrhotic patients. J Infect Dis 1983;147:1011-7.
31. 31. Hoefs JC, Runyon BA. Spontaneous bacterial peritonitis. Dis Mon 1985; 3(9):1-48.
32. 32. Bhuva M, Ganger D, Jensen D. Spontaneous bacterial peritonitis: an update on evaluation, management and prevention. Am J Med 1994;97:169-75.
33. 33. Singh N, Rihs JD, Gayowski T, Mieles L, Yu VL. Improved detection of spontaneous bacterial peritonitis with BACTEC as compared with conventional culture methods. Diagn Microbiol Infect Dis 1994;19:1-4.
34. 34. Fong T, Akriviadis EA, Runyon BA, Reynolds TB. Polymorphonuclear cell count response and duration of antibiotic in SBP. Hepatology 1989;9: 423-6.
35. 35. Goodpasture HC, Gerlach EH, Jones RN, Peterie JD. Optimal cefotaxime dosing for gram-negative bacteremia: effective trough serum bactericidal titer and drug concentrations 8 and 12 hours after 1 or 2 g infusions. Diagn Microbiol Infect Dis 1988;9(2):97-103.
36. 36. Stratton CN. In vitro testing: correlations between bacterial susceptibility body fluid levels and effectiveness of antibacterial therapy. In: Lorian Y, ed. Antibiotics in laboratory medicine (3rd ed.). Baltimore: Williams and Wilkins, 1991.